Loading
NASDAQHealthcareBiotechnology
Latest quote
$24.5943
−$0.9357 · -3.67%
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Regular session
$24.5943
−$0.9357 · -3.67%
Regular session · ET · Market data may be delayed.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Day range
Current $24.5943
52-week range
Current $24.5943
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
48
Elevated Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Day range
Current $24.5943
52-week range
Current $24.5943
| Metric (USD) | FY2025 |
|---|---|
| Research and development | 76.61M USD |
| Selling, general, and administrative | 14.68M USD |
| Operating expenses | 91.29M USD |
| Interest income | 6.18M USD |
| Depreciation and amortization | 42K USD |
| Operating income | −91.29M USD |
| Net income | −85.2M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$60.00
143.96% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI18.56M0.00%2.3T USD0.03%$379.02-0.53%
iShares Russell 2000 ETFIWM12.08M0.02%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF6.77M0.01%95.4B USD0.05%$232.66-0.36%
State Street SPDR S&P Pharmaceuticals ETFXPH3.64M0.79%462.1M USD0.35%$63.23+0.51%
Vanguard Russell 2000 ETFVTWO3.41M0.02%18B USD0.06%$112.1-0.10%
iShares Russell 2000 Growth ETFIWO2.97M0.02%14.25B USD0.24%$352.93-0.69%
Schwab U.S. Small-Cap ETFSCHA2.32M0.01%21.7B USD0.03%$32.6096-0.00%
T. Rowe Price Small-Mid Cap ETFTMSL1.86M0.06%3.05B USD0.55%$40.875-0.16%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAT. Rowe Price Small-Mid Cap ETFTMSLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
